SCHEMBL1884079

SCHEMBL1884079

CC(C)c1cccc(C(C)C(N)=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
CYP3A4 P08684 2/20 0.48
HPGD P15428 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
CA2 P00918 2/20 0.48
MDM4 O15151 1/20 0.48
CA1 P00915 1/20 0.48
TP53 P04637 1/20 0.48
TYR P14679 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
CA5A P35218 1/20 0.48
HTT P42858 1/20 0.48
MDM2 Q00987 1/20 0.48
CA9 Q16790 1/20 0.48
HDAC2 Q92769 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884076 1.00 MAPT (0.48) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL11213811 0.86 MEN1 (0.50) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL27755021 0.83 MAPT (0.52) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL1617654 0.82 ADRB1 (0.55) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL1888604 0.82 CPN1 (0.49) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL3053512 0.82 PARP1 (0.50) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL1343675 0.82 PTGS1 (0.62) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL1345333 0.82 PTGS1 (0.62) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL1343681 0.82 PTGS1 (0.62) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL23721865 0.81 PARP1 (0.48) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939521-B2 2-arylpropionic acid derivatives and pharmaceutical compositions containing them DompePHA.R.MA S.p.A. (IT) 2011-05-10 US disclosed
EP-1856031-B1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-02-25 EP disclosed
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them DOMPE' PHA.R.MA.S.P.A. (IT) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them C3AR1, C5AR2, C5AR1 MAPT 4400/4885SMN1; SMN2 2181/4885KDM4E 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.